Steroid shot during surgery may cut cancer recovery risks

NCT ID NCT03875690

Ongoing Disease control Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether a single high dose of the steroid methylprednisolone, given during surgery, can reduce major complications in 1200 people undergoing elective surgery for digestive cancers. The goal is to calm harmful inflammation that can worsen outcomes. Results will compare complication rates within 30 days between the steroid and placebo groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: methylprednisolone (a corticosteroid)
What this could lead to: If it works, this could reduce serious complications after digestive cancer surgery, potentially improving recovery and survival.
What could go wrong: This is a single high-dose treatment, not a cure. It may not reduce complications as hoped, and corticosteroids have known risks like infection or blood sugar issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIGESTIVE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ELECTIVE SURGERY FOR ANY DIGESTIVE CANCER

Contacts and locations

Locations

Chu de Dijon

Dijon, 21079, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.